Close Menu

stock offering

NEW YORK (GenomeWeb News) – CombiMatrix said today that it anticipates up to $10.4 million in net proceeds from a public offering of its securities.

NEW YORK (GenomeWeb News) – Atossa Genetics has filed a shelf registration to potentially offer from time to time up to $40 million in securities.

NEW YORK (GenomeWeb News) – Accelerate Diagnostics has filed a shelf registration to publicly offer from time to time up to $150 million of securities.

Tekmira Pharmaceuticals this week announced that it has completed the public offering of $30 million of its common stock.

NEW YORK (GenomeWeb News) – Venaxis, which is developing a multi-biomarker test for appendicitis, filed a shelf registration to publicly offer up to $20 million of its stock.

NEW YORK (GenomeWeb News) – Cancer Genetics said after the close of the market last night that it had priced its offering of 2,858,000 shares of common stock at $14 per share.

NEW YORK (GenomeWeb News) – Cancer Genetics today increased the proposed amount it is seeking to raise from a public offering of its common stock.

NEW YORK (GenomeWeb News) – Cancer Genetics has filed to raise up to $46 million in a public offering of its stock.

NEW YORK (GenomeWeb News) – Response Genetics today said that it has signed definitive agreements with unnamed institutional investors for the sale of 932,805 shares of the firm's common stock through a registered direct offering.

NEW YORK (GenomeWeb News) – Nanosphere has closed a public offering of common stock that has raised net proceeds of around $27.7 million.

Pages

The US Department of Justice has proposed a rule change to enable DNA to be collected from migrants, the Associated Press reports.

Bernard Fisher, a surgeon who changed how breast cancer is treated, has died at 101, the New York Times reports.

Washington Post columnist writes that she is skeptical about DNA-based diets.

In PNAS this week: recurrent inactivation of DEPDC5 in gastrointestinal stromal tumors, taxonomic reliability of GenBank sequences, and more.